Form 4: Emergent BioSolutions Director Sells Shares

Emergent BioSolutions Inc. Director Sujata Tyagi Dayal sold 8,552 shares of common stock at $10.00 per share under a Rule 10b5-1 trading plan.

Summary

• Sujata Tyagi Dayal, a Director at Emergent BioSolutions Inc. (EBS), reported the sale of 8,552 shares of common stock.
• The transaction occurred on November 7, 2025.
• Each share was sold at a price of $10.00.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on August 8, 2025.
• Following this transaction, Sujata Tyagi Dayal directly beneficially owns 88,980 shares of Emergent BioSolutions Inc. common stock.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling, although the impact is somewhat mitigated by the transaction being part of a pre-arranged Rule 10b5-1 trading plan, which suggests it was not based on immediate, non-public information.

Negatives

• A director selling shares, even under a pre-arranged plan, can sometimes be perceived negatively by the market as it may suggest a lack of confidence or a desire to reduce exposure to the company's stock.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the director's sale of shares as a potential lack of confidence in the company's near-term prospects, which could lead to negative sentiment or downward pressure on the stock price.

Key Dates

Recommendation

While insider selling can be a negative signal, this transaction was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not necessarily based on new, adverse information. Without additional context on the company's fundamentals or other market factors, a single insider sale, even by a director, does not warrant a strong 'sell' recommendation. Investors should 'hold' and monitor future developments and broader company performance.

Keywords

Emergent BioSolutions, EBS, Form 4, Insider Transaction, Stock Sale, Director, Sujata Tyagi Dayal, Rule 10b5-1